Understanding how B cells are activated and regulated
Identifying, Characterizing, and Targeting Regulators of B Cell Activation
This study is looking at how B cells, which are important for fighting infections, get activated when they meet germs, and it aims to understand how certain signals can help them produce antibodies or lead to problems like autoimmune diseases and cancers, with the hope of finding better treatments for these issues.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10933413 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind B cell activation, focusing on how signals are transmitted through B cell receptors (BCR) when they encounter antigens. By studying the role of co-receptors like CD19, the research aims to uncover how these signals can lead to the production of antibodies and how their dysregulation can contribute to autoimmune diseases and cancers. The approach involves characterizing the interactions and regulatory components that influence B cell responses, which could lead to more targeted therapies for conditions involving B cell dysfunction.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with autoimmune diseases or B cell malignancies who may benefit from targeted therapies.
Not a fit: Patients with conditions unrelated to B cell dysfunction or those who do not have B cell-related diseases may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for autoimmune diseases and B cell malignancies with fewer side effects than current therapies.
How similar studies have performed: Previous research has shown promise in targeting B cell signaling pathways, indicating that this approach could lead to significant advancements in treatment.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Susa, Katherine Julia — University of California, San Francisco
- Study coordinator: Susa, Katherine Julia
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.